AIM ImmunoTech (AIM)
(Delayed Data from AMEX)
$0.27 USD
-0.02 (-8.18%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $0.24 -0.03 (-10.18%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMBalance Sheet
Fiscal Year End for AIM ImmunoTech Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 13 | 34 | 48 | 39 | 9 |
Receivables | 1 | 2 | 2 | 1 | 1 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 0 | 0 | 0 | 0 | 1 |
Total Current Assets | 15 | 36 | 50 | 40 | 10 |
Net Property & Equipment | 0 | 0 | 4 | 6 | 7 |
Investments & Advances | 0 | 0 | 0 | 15 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 2 | 2 | 2 | 2 | 1 |
Deposits & Other Assets | 2 | 1 | 1 | 1 | 1 |
Total Assets | 19 | 40 | 58 | 65 | 20 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 6 | 0 | 0 | 0 | 0 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 2 | 1 | 0 | 0 | 0 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 9 | 1 | 1 | 1 | 1 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 4 |
Non-Current Capital Leases | 0 | 0 | 0 | 2 | 2 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 9 | 2 | 1 | 3 | 7 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 1 | 1 | 1 | 1 | 1 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 419 | 418 | 417 | 403 | 340 |
Retained Earnings | -410 | -381 | -361 | -342 | -328 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 10 | 38 | 57 | 61 | 13 |
Total Liabilities & Shareholder's Equity | 19 | 40 | 58 | 65 | 20 |
Total Common Equity | 10 | 38 | 56 | 61 | 12 |
Shares Outstanding | 48.80 | 48.00 | 46.50 | 40.60 | 8.20 |
Book Value Per Share | 0.20 | 0.79 | 1.21 | 1.49 | 1.48 |
Fiscal Year End for AIM ImmunoTech Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 10 | 11 | 13 | 22 | 28 |
Receivables | 0 | 0 | 1 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 0 | 0 | 0 | 0 | 0 |
Total Current Assets | 10 | 11 | 15 | 23 | 29 |
Net Property & Equipment | 0 | 0 | 0 | 0 | 0 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 2 | 2 | 2 | 2 | 2 |
Deposits & Other Assets | 2 | 2 | 2 | 2 | 2 |
Total Assets | 16 | 16 | 19 | 28 | 34 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 2 | 2 | 0 | 0 | 0 |
Accounts Payable | 5 | 7 | 6 | 3 | 2 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 1 | 1 | 2 | 2 | 1 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 9 | 10 | 9 | 5 | 3 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 1 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 10 | 11 | 9 | 5 | 3 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 1 | 1 | 1 | 1 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 423 | 419 | 419 | 419 | 419 |
Retained Earnings | -417 | -415 | -410 | -397 | -389 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 6 | 5 | 10 | 23 | 30 |
Total Liabilities & Shareholder's Equity | 16 | 16 | 19 | 28 | 34 |
Total Common Equity | 6 | 4 | 10 | 22 | 29 |
Shares Outstanding | 57.10 | 50.70 | 48.80 | 48.80 | 48.40 |
Book Value Per Share | 0.11 | 0.08 | 0.20 | 0.45 | 0.61 |